Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-06-30
2000-10-10
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31495
Patent
active
061302198
ABSTRACT:
Drug and multidrug resistant modulators of the formula: ##STR1## where R.sup.1 and R.sup.2 are independently hydrogen or halo; A is --CH.sub.2 --CH.sub.2 --, --CH.sub.2 --CHR.sup.4 --CH.sub.2 --, or --CH.sub.2 --CHR.sup.5 --CHR.sup.6 --CH.sub.2 --, where R.sup.4 is --H, --OH, or acyloxy; one of R.sup.5 or R.sup.6 is --H, --OH, or acyloxy, and the other is --H; R.sup.3 is a polyaryl; and pharmaceutically acceptable salts and solvates thereof, are described and claimed. Use of the new compounds in the preparation of pharmaceutical compositions is described and claimed. In addition, methods for treating drug and multidrug resistance in various diseases using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed. Also, methods of enhancing oral bioavailability of a drug and methods of enhancing bioavailability of a drug to the brain using a compound, or pharmaceutically acceptable salt or solvate thereof, of this invention are described and claimed.
REFERENCES:
patent: 3133925 (1964-05-01), Cusic
patent: 4251539 (1981-02-01), Thieme et al.
patent: 4305951 (1981-12-01), Frickel et al.
patent: 4428950 (1984-01-01), Franke et al.
patent: 4540697 (1985-09-01), Franke et al.
patent: 4918073 (1990-04-01), Ruger
patent: 5112817 (1992-05-01), Fukazawa et al.
patent: 5523304 (1996-06-01), Sunkara
patent: 5596002 (1997-01-01), Hofheinz et al.
patent: 5654304 (1997-08-01), Pfister et al.
patent: 5776939 (1998-07-01), Kroin et al.
patent: 5889007 (1999-03-01), Pfister et al.
Reutz, et al., "The pfmdrl gene of Plasmodium falciparum confers cellular resistance to antimalarial drugs in yeast cells," Proc. Natl. Acad. Sci., vol. 93, 9942-9947 (1996).
Terao, et al., "Active Secretion of Drugs from the Small Intestinal Epithelium in Rats by P-Glycoprotein Functioning as an Absorption Barrier," J. Pharm. Pharmacol., 48, 1083-1089 (1996).
Pfister, et al., "Methanodibenzosuberylpiperazines as Potent Multidrug Resistance Reversal Agents," Bioorganic and Medicinal Chemistry Letters, vol. 5, No. 21, 2473-2476 (1995).
Bellamy, et al., "The Clinical Relevance of Multidrug Resistance," Cancer Investigation, vol. 8, No. 5, 547-562 (1990).
Alfred Burger, "Isosterism and Bioisosterism as Guides to Structural Variations," Medicinal Chemistry, Second Edition, 72-78 (1960).
Nakanishi, et al., "Studies on cardiovascular drugs.5.1-amino-3-phenoxy-2-propanol derivatives as beta-adrenergic-blocking agents," Journal of Medicinal Chemistry, vol. 15, No. 1, 45-48 (1972).
Chemical Abstracts, Abstract No. 97493, vol. 78, No. 15, 466 (1973).
Chemical Abstracts, Abstract No. 170660a, vol. 82, No. 25, 515 (1975).
Hunter, et al., "Functional Expression of P-glycoprotein in Apical Membranes of Human Intestinal Caco-2 Cells," The Journal of Biological Chemistry, vol. 268, No. 20, 14991-14997 (1993).
Patel, et al., "Multidrug Resistance in cancer chemotherapy," International New Drugs, 12, 1-13 (1994).
"Modulation of Multidrug Resistance; At the Threshold," Journal of Clinical Oncology, vol. 11, No. 9, 1629-1635 (1993).
Lannoy, et al., "The MDR1 Gene Product, P-glycoprotein Mediates the Transport of the Cardiac Glycoside, Digoxin," Biochemical and Biophysical Research Communications, vol. 189, No. 1, 551-557 (1992).
Hunter, et al., "Drug Absorption Limited by P-glycoprotein-Mediated Secretory Drug Transport in Human Intestional Epithelial Caco-2 Cell Layers," Pharmaceutical Research, vol. 10, No. 5, 743 (1992).
Tatsuta, et al., "Functional Involvement of P-glycoprotein in Blood-Brain Barrier," The Journal of Biological Chemistry, vol. 267, No. 28, 20383-20391 (1992).
Hegmann, et al., "Expression and Functional Activity of P-glycoprotein in Cultured Cerebral Capillary Endothelial Cells," Cancer Research, 52, 6969-6975 (1992).
Horton, et al., "Modulation by Verapamil of Vincristine Pharmacokinetics and Toxicity in Mice Bearing Human Tumor Xenografts," Biochemical Pharmacology, vol. 38, No. 11, 1727-1736 (1989).
Augustijins, et al., "Evidence for A Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporin A Transport," Biochemical and Biophysical Research Communication, vol. 197, No. 2, 360-365 (1993).
"Restricted transport of cyclosporin A across the blood-brain barrier by a multidrug transporter, P-glycoprotein," Biochemical Pharmacology, vol. 46, No. 6, 1096-1099 (1993).
Bruno, et al., "Effect of Exposure to Calcium Entry Blockers on Doxorubicin Accumulation and Cytotoxicity in Multidrug-Resistant Cells," Journal of the National Cancer Institute, vol. 82, No. 5, 419-424 (1990).
Slate, et al., Modulation of Dexorubicin Efficacy in P388 Leukemia following Co-administration of Verapamil in Mini-Osmotic Pumps, In Vivo, 7, 519-524 (1993).
Slate, et al., "RS-33295-198: A Novel, Potent Modulator of P-glycoprotein Mediated Multidrug Resistance," Anticancer Research, vol. 15, 811-814 (1995).
Kroin Julian Stanley
Norman Bryan Hurst
Cook Rebecca
Dawalt Elizabeth A.
Eli Lilly and Company
LandOfFree
Drug resistance and multidrug resistance modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Drug resistance and multidrug resistance modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Drug resistance and multidrug resistance modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2257143